This week Montana became the first U.S. state to allow any biotechnology company to sell an experimental drug directly to consumers. Under the new framework, companies can seek review after very early testing — in some cases involving as few as ten healthy volunteers — and the review process reportedly costs $12,500. Firms may set their own prices and distribute products through experimental clinics.
Whereas other states typically restrict such access to patients with terminal illnesses, Montana’s rule opens the pathway to anyone who provides informed consent and can pay, including people seeking longevity interventions. A review board composed of a physician, scientists, and an ethicist must sign off. Two candidate drugs — one for neuropathy and one for hearing loss — are already under review.
Why this matters
The change allows products to reach paying patients before the completion of full clinical trials. That reverses the usual sequence in which investigational drugs are evaluated in controlled clinical studies with volunteer participants and established safety monitoring. Under Montana’s approach, patients assume much of the financial cost of access and a greater share of potential risk, because earlier-stage evidence may be limited.
Supporters argue the policy expands access and accelerates availability for those excluded from traditional trials. Critics warn it commodifies early experimentation, potentially exposing consumers to poorly studied therapies and reducing incentives to conduct thorough, large-scale testing that demonstrates safety and efficacy.
Context: AI and a faster pipeline of candidates
Proponents point to another development: artificial intelligence is producing drug candidates at a pace that can outstrip traditional trial capacity. The discussion referenced a recent example in which Roche advanced an AI-identified cancer marker into trials before its mechanism was fully explained. Montana’s rule reflects a similar inversion: rather than waiting for complete understanding through traditional evidence generation, it permits patient access while formal testing continues.
Implications and open questions
Montana’s decision may speed patient access to novel therapies, but it raises questions about patient protection, the distribution of risk and cost, and the role of paid early access as an alternative to standard clinical trials. The outcomes of the two currently reviewed drugs and the longer-term effects of this regulatory change on drug development and patient safety will require continued monitoring.
